We are proud to share that our IDS i10 machine may play a role in early sepsis detection.

Volition, an epigenetic company focused on advancing the science of epigenetics, is committed to saving lives through the earlier detection of life-altering diseases.

Its latest breakthrough could play a vital role in diagnosing sepsis early, potentially saving thousands of lives.

Sepsis is a life-threatening disease that causes 48,000 deaths a year. It can also have devastating consequences for survivors, including weakened immune systems and limb amputations, if not detected quickly enough. For every hour that antibiotics are delayed in sepsis patients, their mortality risk increases by 8%.

Volition is working on an observational clinical study that may identify the future risk of sepsis in patients via a blood test. The IDS i10 system forms a key part of this groundbreaking research.

This trial is currently in place at St Thomas’ Hospital, which admits around 1,000 sepsis patients into intensive care units every year. 

The test uses a sample of patients’ blood to detect H3.1, a protein created by the body’s immune system that is associated with sepsis. The higher the level of this protein, the greater the future risk of sepsis in the patient. 

The highly accurate next-generation analysis IDS i10 system is being used to perform this test. It can handle up to 170 tests an hour and optimises uptime, making it the ideal instrument for this essential test.

We look forward to the results from this clinical observational study and hope to see this test save many lives.

BBC Morning Live recently covered this innovation – watch the feature now.